Skip to main content
ArticleOPEN ACCESS

Novel antidotes for target specific oral anticoagulants

Experimental Hematology and Oncology
DOI: 10.1186/s40164-015-0020-3
30Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.

Cite

CITATION STYLE

APA

Das, A., & Liu, D. (2015, September 15). Novel antidotes for target specific oral anticoagulants. Experimental Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s40164-015-0020-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free